Hydrocolloid matrix systems for modified release of diltiazem hydrochloride: A step toward personalized cardiovascular therapy
Scripta Scientifica Medica · 2026
DOI: 10.14748/8ag18j40 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scripta Scientifica Medica, 2026. Verfasst von Nadezhda Ivanova und 2 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Introduction
Sustained-release dosage forms represent a valuable tool in the pharmaceutical development of drugs with high water solubility and a short biological half-life (t₁/₂), as they help optimize dosing regimens and improve therapeutic efficacy. Hydrocolloid matrices offer a practical solution for controlling drug release through swelling and erosion, thus ensuring prolonged dissolution and diffusion of the active substance.
Aim
This study aimed to investigate various hydrocolloid matrices as sustained drug delivery platforms for diltiazem. Materials and Methods: Diltiazem hydrochloride, a highly water-soluble and biochemically unstable drug with a short half-life (3.5–4 h), was formulated into hydrocolloid matrix tablets composed of hydroxypropyl methylcellulose (HPMC), sodium carboxymethylcellulose (CMC-Na), or a 1:1 combination of the two cellulose derivatives. The different hydrocolloid formulations were subjected to pharmacopoeial dissolution and swelling studies in simulated gastric fluid (HCL 0.1 M) and simulated intestinal fluid (phosphate buffer saline—PBS, pH 6.8).
Results
Pronounced differences were observed in the in vitro behavior of the matrices in PBS 6.8, where the highest swelling index was recorded for the CMC-Na matrix (476.9%), followed by the combined HPMC:CMC-Na matrix (323.3%) and the HPMC matrix (104.0%). Increased swelling was associated with slower drug release, indicating that extension of the diffusion pathway represented the dominant release-controlling mechanism.
Conclusion
This study provides an in vitro comparison of three hydrocolloid models for the sustained delivery of diltiazem, enabling formulation optimization according to specific therapeutic goals and supporting the development of personalized dosage forms (e.g., through 3D printing technologies).
Zitieren
APA
Ivanova, N., Stamova, S., & Andonova, V. (2026). Hydrocolloid matrix systems for modified release of diltiazem hydrochloride: A step toward personalized cardiovascular therapy. Scripta Scientifica Medica. https://doi.org/10.14748/8ag18j40
Vancouver
Ivanova N, Stamova S, Andonova V. Hydrocolloid matrix systems for modified release of diltiazem hydrochloride: A step toward personalized cardiovascular therapy. Scripta Scientifica Medica. 2026. doi:10.14748/8ag18j40
BibTeX
@article{Ivanova2026,
author = {Ivanova, Nadezhda and Stamova, Sylvia and Andonova, Velichka},
title = {Hydrocolloid matrix systems for modified release of diltiazem hydrochloride: A step toward personalized cardiovascular therapy},
journal = {Scripta Scientifica Medica},
year = {2026},
doi = {10.14748/8ag18j40}
}
EUVIMED